Safety Profile Remains Consistent When Darolutamide Is Added to ADT for nmCRPC
September 26th 2021Acceptable safety was noted with the addition of darolutamide to androgen deprivation therapy and resulted in infrequent extra adverse effects versus placebo in men with nonmetastatic castration-resistant prostate cancer.